GROWTHFORGE · BEACON · SOURCE-BACKED SIGNAL
Previfenon® as Chemoprophylaxis of COVID-19 in Health Workers
NCT04446065 is on the Cheap-to-Truth Radar because its public ClinicalTrials.gov record contains a recent development signal worth inspecting. This page is not a recommendation or diligence conclusion.
Priority to inspect76/100
StatusWITHDRAWN
PhasePHASE2 / PHASE3
Lead sponsorMELISA Institute Genomics & Proteomics Research SpA
Last update2026-10-19
Public-record facts
| Intervention | Previfenon® (DRUG), Placebo (DRUG) |
|---|---|
| Condition | COVID-19, SARS-CoV2 |
| Enrollment | 0 |
| Why stopped | The protocol was withdrawn because enrollment did not begin. |
| Results posted | No / not indicated |
Why Beacon surfaced it
- The record is withdrawn and was updated 2026-10-19.
- It is an interventional PHASE2/PHASE3 study with a named drug/drug intervention.
- The lead sponsor is classified as industry.
- The record states a reason for stopping, creating a concrete diligence question.
What Cheap-to-Truth would verify next
- Was the stopping reason scientific, operational, financial, strategic, or mixed?
- What human safety and efficacy evidence actually exists beyond the registry summary?
- Who controls the relevant rights, and are they practically obtainable?
- Is there an indication and endpoint where a smaller experiment could answer the key decision?
- Would the resulting data be usable by the regulator that matters?
Source: ClinicalTrials.gov NCT04446065. Registry information is sponsor/investigator submitted; verify primary evidence before making development decisions.